Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial
Cancer · 2025
DOI: 10.1002/cncr.35628 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von Emanuela Palmerini und 19 weiteren Autor:innen. Beteiligte Einrichtung: Osteoncology, Bone and Soft Tissue Tumors and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Hauptthemen laut MEDLINE: Sunitinib, Nivolumab, Bone Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Spanish Group for Research on Sarcoma, Italian Sarcoma Group, Bristol-Myers Squibb.
Abstract (Originalsprache)
Background
Herein, we present the results of the phase 2 IMMUNOSARC study (NCT03277924), investigating sunitinib and nivolumab in adult patients with advanced bone sarcomas (BS).
Methods
Progressing patients with a diagnosis of BS were eligible. Treatment was comprised of sunitinib (37.5 mg/day on days 1–14, 25 mg/day afterword) plus nivolumab (3 mg/kg every 2 weeks). Primary end point was progression‐free survival rate (PFSR) at 6 months based on central radiology review. Secondary end points were overall survival (OS), overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and safety.
Results
A total of 46 patients were screened, 40 patients entered the study, and 38 underwent central radiological review and were evaluable for primary end point. Median age was 47 years (range, 21–74). Histologies include 17 (43%) osteosarcoma, 14 chondrosarcoma (35%, 10 conventional, four dedifferentiated [DDCS]), eight (20%) Ewing sarcoma, and one (2%) undifferentiated pleomorphic sarcoma. The PFSR at 6 months was 42% (95% confidence interval [CI], 27–58). With a median follow‐up of 39.8 months (95% CI, 37.9–41.7), the median PFS and OS were 3.8 months (95% CI, 2.7–4.8) and 11.9 months (95% CI, 5.6–18.2). ORR by RECIST was 5%, with two of 38 partial responses (one of four DDCS and one of 17 osteosarcoma), 19 of 38 (50%) stable disease, and 17 of 38 (45%) progressions. Grade ≥3 adverse events were neutropenia (six of 40, 15%), anemia (5/40, hypertension (6/40, 15%), 12.5%), ALT/AST elevation (5/40, 12.5%), and pneumonitis (1/40, 2.5%). Seventeen percent of patients discontinued treatment due to toxicity, including a treatment‐related grade 5 pneumonitis Conclusion The trial met its primary end point in the BS cohort with >15% of patients progression‐free at 6 months. However, the toxicity profile of this regimen was relevant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Osteoncology, Bone and Soft Tissue Tumors and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.
- Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
- Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
- Hospital General de Villalba, Madrid, Spain.
ORCID-Profile: Emanuela Palmerini, Javier Martinez Trufero, Silvia Stacchiotti
Förderung
- Spanish Group for Research on Sarcoma
- Italian Sarcoma Group
- Bristol-Myers Squibb
- Pfizer
- CARISBO
Zitieren
APA
Palmerini, E., Lopez Pousa, A., Grignani, G., Redondo, A., Hindi, N., Provenzano, S., Sebio, A., Lopez Martin, J. A., Valverde, C., Martinez Trufero, J., Gutierrez, A., de Alava, E., Aparisi Gomez, M. P., D'Ambrosio, L., Collini, P., Bazzocchi, A., Moura, D. S., Ibrahim, T., Stacchiotti, S., & Broto, J. M. (2025). Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial. Cancer. https://doi.org/10.1002/cncr.35628
Vancouver
Palmerini E, Lopez Pousa A, Grignani G, Redondo A, Hindi N, Provenzano S, et al. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial. Cancer. 2025. doi:10.1002/cncr.35628
BibTeX
@article{Palmerini2025,
author = {Palmerini, Emanuela and Lopez Pousa, Antonio and Grignani, Giovanni and Redondo, Andres and Hindi, Nadia and Provenzano, Salvatore and Sebio, Ana and Lopez Martin, Jose Antonio and Valverde, Claudia and Martinez Trufero, Javier and Gutierrez, Antonio and de Alava, Enrique and Aparisi Gomez, Maria Pilar and D'Ambrosio, Lorenzo and Collini, Paola and Bazzocchi, Alberto and Moura, David S and Ibrahim, Toni and Stacchiotti, Silvia and Broto, Javier Martin},
title = {Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35628}
}
EUVIMED